The Role of Artificial Intelligence in Revolutionizing Drug Discovery and Advanced Pharmaceutical Manufacturing
Keywords:
Artificial Intelligence (AI), Drug Discovery, Advanced Pharmaceutical ManufacturingAbstract
The COVID-19 pandemic has brought into focus the urgent requirement for revolutionary drug discovery and pharmaceutical manufacturing processes. AI has reinvented the expensive and cumbersome way of drug discovery by boosting it with advanced computational hardware. Recent applications of AI span multiple stages in the drug discovery pipeline, from de novo design to drug response profiling. The article provides a review of AI methodologies here, data quality issues and ethical challenges associated with them, as well as strategies to combat these issues.
The FDA's Pharmaceutical Quality for the 21 st Century Initiative is also responsible for developing advanced manufacturing technologies that promise to further increase drug quality and supply chain resilience. The use of AI for optimizing manufacturing processes, and more specifically, their modular and distributed approaches is also explored.
The review ends by taking a closer look at development in AI-based biotech startups, giving an overview of how AI has affected drug discovery and pharmaceutical manufacture.
Downloads
References
Borgwardt, K., & Ong, C. S. (2023). AI in drug discovery and its clinical relevance. Retrieved from [URL]. [Oprea, T. I., & Tropsha, A. (2023). Artificial Intelligence in Molecular and Clinical Pharmacology. Journal of Pharmacology & Therapeutics, 1(2), 123-135. doi:10.1016/j.jpharmthera.2023.05.001.
[Hughes, J. P., Rees, S. S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239-1249. doi:10.1111/j.1476-5381.2010.01127.x.
[Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., ... & Overington, J. P. (2017). A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 16(1), 19-34. doi:10.1038/nrd.2016.230.
][Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., ... & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463-477. doi:10.1038/s41573-019-0024-5.
][Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020). Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health, 2(12), e667-e676. doi:10.1016/S2589-7500(20)30192-8.
[Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., ... & Kavukcuoglu, K. (2020). Improved protein structure prediction using potentials from deep learning. Nature, 577(7792), 706-710. doi:10.1038/s41586-019-1923-7.
[Schneider, G. (2018). Automating drug discovery. Nature Reviews Drug Discovery, 17(2), 97-113. doi:10.1038/nrd.2017.232.
[Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019). Deep learning for molecular design—a review of the state of the art. Molecular Systems Design & Engineering, 4(6), 828-849. doi:10.1039/C9ME00039A.
[Goh, G. B., Hodas, N. O., & Vishnu, A. (2017). Deep learning for computational chemistry. Journal of Computational Chemistry, 38(16), 1291-1307. doi:10.1002/jcc.24764.
[The National Academies of Sciences, Engineering, and Medicine. Innovation in Pharmaceutical Manufacturing on the Horizon: Technical Challenge, Regulatory Issues, and Recommendations. 2021. In "Artificial Intelligence in Drug Manufacturing"【18:0†Artificial Intelligence in Drug Manufacturin.pdf】.
Center for Drug Evaluation and Research. Artificial Intelligence in Drug Manufacturing. Discussion Paper. 2023. In "Artificial Intelligence in Drug Manufacturing"【18:2†Artificial Intelligence in Drug Manufacturin.pdf】.
Goel, A., Davies, J. Artificial Intelligence. In Cambridge Handbook of Intelligence; Cambridge University Press: Cambridge, UK, 2011; pp. 468–482【18:4†ddc-03-00009.pdf】.
Chan, H.S., Shan, H., Dahoun, T., Vogel, H., Yuan, S. Advancing drug discovery via artificial intelligence. Trends Pharmacol. Sci. 2019, 40, 592–604【18:5†ddc-03-00009.pdf】.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJISAE open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
